These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 25389779)

  • 1. Performance of two HCV RNA assays during protease inhibitor-based triple therapy in patients with advanced liver fibrosis and cirrhosis.
    Maasoumy B; Hunyady B; Calvaruso V; Makara M; Vermehren J; Haragh A; Susser S; Bremer B; Cloherty G; Manns MP; Craxì A; Wedemeyer H; Sarrazin C
    PLoS One; 2014; 9(11):e110857. PubMed ID: 25389779
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of HCV kinetics on treatment outcome differs by the type of real-time HCV assay in NS3/4A protease inhibitor-based triple therapy.
    Ogawa E; Furusyo N; Murata M; Hayashi T; Shimizu M; Mukae H; Toyoda K; Hotta T; Uchiumi T; Hayashi J
    Antiviral Res; 2016 Feb; 126():35-42. PubMed ID: 26692214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Significance of Two Real-Time PCR Assays for Chronic Hepatitis C Patients Receiving Protease Inhibitor-Based Therapy.
    Inoue T; Hmwe SS; Shimada N; Kato K; Ide T; Torimura T; Kumada T; Toyoda H; Tsubota A; Takaguchi K; Wakita T; Tanaka Y
    PLoS One; 2017; 12(1):e0170667. PubMed ID: 28118381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance characteristics of the COBAS Ampliprep/COBAS TaqMan v2.0 and the Abbott RealTime hepatitis C assays - implications for response-guided therapy in genotype 1 infections.
    Taylor N; Haschke-Becher E; Greil R; Strasser M; Oberkofler H
    Antivir Ther; 2014; 19(5):449-54. PubMed ID: 24430620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.
    Maasoumy B; Cobb B; Bremer B; Luk K; Halfon P; Aslam S; Manns MP; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2014 Jan; 39(1):85-92. PubMed ID: 24206524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Can the Abbott RealTime hepatitis C virus assay be used to predict therapeutic outcomes in hepatitis C virus-infected patients undergoing triple therapy?
    Ikeda H; Okuse C; Watanabe T; Matsumoto N; Matsunaga K; Shigefuku R; Hattori N; Hiraishi T; Fukuda Y; Noguchi Y; Ishii T; Shima J; Nakahara K; Yamamoto H; Yasuda H; Yotsuyanagi H; Koike K; Itoh F; Suzuki M
    Turk J Gastroenterol; 2016 Mar; 27(2):165-72. PubMed ID: 27015621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Okada K; Kainuma M; Hayashi J
    Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of lead-in silibinin and subsequent triple therapy in difficult-to-treat HIV/hepatitis C virus-coinfected patients.
    Braun DL; Rauch A; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Metzner KJ; Böni J; Weber R; Fehr J
    HIV Med; 2014 Nov; 15(10):625-30. PubMed ID: 24894776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical significance of residual viremia detected by two real-time PCR assays for response-guided therapy of HCV genotype 1 infection.
    Vermehren J; Aghemo A; Falconer K; Susser S; Lunghi G; Zeuzem S; Colombo M; Weiland O; Sarrazin C
    J Hepatol; 2014 May; 60(5):913-9. PubMed ID: 24424305
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictive variables of sustained virological response after early discontinuation of triple therapy with telaprevir for genotype-1 HCV infection.
    Acero Fernández D; Morillas Cunill R; Ferri Iglesias MJ; Torras Collell X; Vergara Gómez M; Zaragoza Velasco N; López Nuñez C; Forné Bardera M; Delgado Gómez M; Barenys Lacha M; Torres Salinas M; Villar Fernández M; Durández Lázaro R; Mariño Mendez Z
    Gastroenterol Hepatol; 2016; 39(6):377-84. PubMed ID: 26614733
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy.
    Sáez-Royuela F; Linares P; Cervera LA; Almohalla C; Jorquera F; Lorenzo S; García I; Karpman G; Badia E; Vallecillo MA; Moncada A; Calvo S; Olcoz JL;
    Eur J Gastroenterol Hepatol; 2016 Mar; 28(3):305-12. PubMed ID: 26636405
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV RNA quantification with different assays: implications for protease-inhibitor-based response-guided therapy.
    Fevery B; Susser S; Lenz O; Cloherty G; Perner D; Picchio G; Sarrazin C
    Antivir Ther; 2014; 19(6):559-67. PubMed ID: 24584086
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of on-treatment HCV RNA during direct antiviral therapy using two different COBAS TaqMan HCV assays.
    Vermehren J; Bourlière M; Pol S; Marcellin P; Hyland RH; Jiang D; Brainard DM; Zeuzem S; Welzel TM
    J Clin Virol; 2017 Apr; 89():51-56. PubMed ID: 28259054
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicentric performance analysis of HCV quantification assays and its potential relevance for HCV treatment.
    Wiesmann F; Naeth G; Berger A; Hirsch HH; Regenass S; Ross RS; Sarrazin C; Wedemeyer H; Knechten H; Braun P
    Med Microbiol Immunol; 2016 Jun; 205(3):263-8. PubMed ID: 26666643
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
    Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
    Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.
    Bailly F; Virlogeux V; Dufour C; Pradat P; Hézode C; Larrey D; Alric L; Samuel D; Bourlière M; Métivier S; Zarski JP; Fontaine H; Loustaud-Ratti V; Serfaty L; Bronowicki JP; Carrat F; Zoulim F;
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39(4):443-50. PubMed ID: 25636238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
    Bruno S; Vierling JM; Esteban R; Nyberg LM; Tanno H; Goodman Z; Poordad F; Bacon B; Gottesdiener K; Pedicone LD; Albrecht JK; Brass CA; Thompson S; Burroughs MH
    J Hepatol; 2013 Mar; 58(3):479-87. PubMed ID: 23183529
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C.
    Martinot-Peignoux M; Khiri H; Leclere L; Maylin S; Marcellin P; Halfon P
    J Clin Virol; 2009 Nov; 46(3):216-21. PubMed ID: 19748822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Boceprevir is highly effective in treatment-experienced hepatitis C virus-positive genotype-1 menopausal women.
    Bernabucci V; Ciancio A; Petta S; Karampatou A; Turco L; Strona S; Critelli R; Todesca P; Cerami C; Sagnelli C; Rizzetto M; Cammà C; Villa E
    World J Gastroenterol; 2014 Nov; 20(44):16726-33. PubMed ID: 25469044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of triple therapy with peginterferon, ribavirin and boceprevir within an early access programme in Spanish patients with hepatitis C genotype 1 with severe fibrosis: SVRw12 analysis.
    Calleja JL; Pascasio JM; Ruiz-Antorán B; Gea F; Bárcena R; Larrubia JR; Pérez-Álvarez R; Sousa JM; Romero-Gómez M; Solá R; de la Revilla J; Crespo J; Navarro JM; Arenas JI; Delgado M; Fernández-Rodríguez CM; Planas R; Buti M; Forns X;
    Liver Int; 2015 Jan; 35(1):90-100. PubMed ID: 25113158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.